[Skip to Content]
[Skip to Content Landing]
Citations 0
October 12, 2005

Abciximab in the Treatment of ST-Segment Elevation Myocardial Infarction

JAMA. 2005;294(14):1760-1761. doi:10.1001/jama.294.14.1760-b

To the Editor: In the meta-analysis by Dr De Luca and colleagues,1 the authors concluded that in the setting of acute ST-segment elevation myocardial infarction (STEMI), adjunctive abciximab should be used in patients treated with primary angioplasty but not in those treated with fibrinolysis. The meta-analysis included 3 trials in which patients receiving either full-dose fibrinolytic drugs or a combination of half-dose fibrinolytic drugs plus abciximab were enrolled (ASSENT 3,2 ENTIRE-TIMI 23,3 GUSTO V4).